# Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk

Study · id `cardio:ct-nct07806279` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07806279](<https://clinicaltrials.gov/study/NCT07806279>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07806279

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT07806279. Randomized; no masking; primary purpose treatment. Start 2026-10-30 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT07806279, source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)
- Planned start: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT07806279, source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07806279, source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07806279, source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT07806279, source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07806279-2026-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk
- Condition: Cardiometabolic Syndrome
- Condition: Obesity and Cardiovascular Risk
- Condition: Overweight , Obesity
- Intervention (Drug): Bupropion 150 mg
- Intervention (Dietary supplement): Lyophilized powder from edible mushrooms
- Intervention (Behavioral): Lifestyle Management
- Lead sponsor: Uppsala University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Uppsala University (`cardio:org-uppsala-university`)

## Provenance

Content hash: 2f384704be4c4b326b850cdb83d21c4195f6353b5dfc09fbc896f911dc187431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
